Navigation Links
Exciton Technologies receives FDA approval to market exSALT(TM)
Date:8/5/2009

EDMONTON, Aug. 5 /PRNewswire/ - Exciton Technologies Inc. today announced that the Company has received approval from the United States Food and Drug Administration (FDA) to market exSALT(TM) SD7 Wound Dressing, a product incorporating Exciton's patented platform coating technology utilizing silver oxysalts as the active ingredient.

"This achievement represents a significant team effort and a strong belief in our product," stated Rod Precht, Exciton's President and Chief Executive Officer. "To date, our technologies have demonstrated superior attributes over other leading silver technologies, allowing us to offer effective products at a significantly lower cost. With the approval from the FDA, we can now finalize our commercialization efforts to launch the exSALT(TM) dressing in North America later this year. In addition to preparing for the launch of the exSALT(TM) dressing, the Company is currently in the process of negotiating licensing and distribution agreements with leading wound care companies to broaden our marketing network globally."

The global wound-care market was $14 billion in 2008 and is expected to exceed $17 billion by 2012. Although silver-based products currently comprise a relatively small portion of this market, it is rapidly growing by 25% annually and is expected to grow to $750 million by 2015 due to the natural therapeutic benefits of silver. According to the Centers for Disease Control and Prevention, hospital-acquired infections in the United States alone cost up to $30 billion a year. Exciton's silver-based products have the potential to capitalize an even larger market by:

    -   Utilizing a more active form of silver;
    -   Reducing costs; and
    -   Being amendable to more applications such as consumer products,
        catheters and orthopedic devices.

    About exSALT(TM)
    ----------------

Silver has powerful antimicrobial properties. In the proper chemical form, it is proven as a highly effective wound-care agent with important benefits for promoting healing and preventing infection. Exciton's exSALT(TM) antimicrobial technology uses a patented chemical deposition technique to form a coating of active species of silver on a wide range of materials. The exSALT(TM) SD7 Wound Dressing targets the advanced wound care market in preventing infection during the treatment of burn and chronic wounds such as diabetic foot ulcers and bed sores. By adjusting the dose of silver and expanding the number of product configurations, Exciton can target a greater portion of the overall market.

    About Exciton Technologies Inc.
    -------------------------------

Exciton Technologies Inc. is an Alberta advanced materials research and development company focused on the creation of technologies for preventing and controlling infection. Currently our valuable portfolio of patentable platform technologies is based on the antimicrobial properties of silver. The Company's technologies offer next-generation, less expensive and environmentally friendly products, enabling the company to participate in many industries, including the wound care and disinfectant markets.

    Forward-looking Statements
    --------------------------

This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.


'/>"/>
SOURCE Exciton Technolgies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
3. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
4. OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.
5. Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software
6. Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
7. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
8. Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies
9. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
10. DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies
11. 4th BTLtec Conference on 24-25 Sep in Graz, Austria features Biomass to Liquids Innovators Sharing Updates on Pyrolysis and Gasification Technologies, Syngas Application, BTL Value Chain and a Site Visit to the Biomass CHP Gussing Plant.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... made significant investments in recruiting top industry experts, and expanding its LATAM network ... provides industry-leading tools for clients to manage their clinical trial projects. , The ...
(Date:4/27/2016)... ... 27, 2016 , ... Cambridge Semantics, the leading provider of Smart ... it has been named to The Silicon Review’s “20 Fastest Growing Big Data Companies ... Semantics serves the needs of end users facing some of the most complex data ...
(Date:4/27/2016)... ... ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” Gardner ... Committee since 1987. Since then, he has served in a number of key leadership ... both the program and exposition committees. In his professional career, Dr. Gardner is the ...
(Date:4/27/2016)... 27, 2016 NanoStruck Technologies ... NSKQB) ( Frankfurt : 8NSK) gibt ... vom 13. August 2015 die Genehmigung von der ... zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu erhöhen, ... Davon wurden 157.900.000 Einheiten mit dem ersten Teil ...
Breaking Biology Technology:
(Date:3/2/2016)... 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ... "Global Biometrics as a Service Market 2016-2020" ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced the ... a Service Market 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ...
(Date:3/1/2016)... FRANCISCO , March 1, 2016  (RSAC Booth ... year, but a whopping $118 billion is lost to ... to overzealous and inaccurate fraud detection. At the RSA ... in the way companies handle authentication by devaluing the ... and behavioral analytics. --> ...
(Date:2/26/2016)... Feb. 26, 2016 ... the "Biometrics Market in MENA: Research ... to their offering. --> ... the "Biometrics Market in MENA: Research ... to their offering. --> ...
Breaking Biology News(10 mins):